Helena Brett-Smith serves as Chief Development Officer of the Company. Prior to joining us, Dr. Brett-Smith worked in clinical drug development at Bristol-Myers Squibb from 2000 until January 2017 in roles of increasing seniority, most recently as Vice President and Head of Fibrosis Full Development. Prior to joining Bristol-Myers Squibb, Dr. Brett-Smith was Director of the HIV Program and outpatient care center at the Hospital of Saint Raphael in New Haven, Connecticut from 1992 to 2000. Dr. Brett-Smith earned her undergraduate degree from Yale University and her M.D. from the Stanford University School of Medicine. She completed her residency in Internal Medicine and a fellowship in Infectious Diseases at the Yale School of Medicine.
Helena Smith is 63, she's been the Chief Development Officer of Trevi Therapeutics since 2017. There are 7 older and 11 younger executives at Trevi Therapeutics. The oldest executive at Trevi Therapeutics, Inc. is Anne VanLent, 72, who is the Independent Director.
Helena's mailing address filed with the SEC is C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 14TH FLOOR, NEW HAVEN, CT, 06510.
Over the last 6 years, insiders at Trevi Therapeutics have traded over $2,844,492 worth of Trevi Therapeutics stock and bought 79,366,506 units worth $381,350,992 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Forest Baskett y Scott D Sandell. On average, Trevi Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $3,549,117. The most recent stock trade was executed by Jennifer L Good on 6 September 2024, trading 6,059 units of TRVI stock currently worth $8,664.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics executives and other stock owners filed with the SEC include: